Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Return on Capital Employed (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Return on Capital Employed for 9 consecutive years, with 0.26% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 31.0% year-over-year to 0.26%, compared with a TTM value of 0.26% through Dec 2025, up 31.0%, and an annual FY2025 reading of 0.33%, up 29.0% over the prior year.
  • Return on Capital Employed was 0.26% for Q4 2025 at Zevra Therapeutics, up from 0.37% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 4.0% in Q3 2022 and bottomed at 0.94% in Q4 2022.
  • Average Return on Capital Employed over 5 years is 0.15%, with a median of 0.43% recorded in 2023.
  • The sharpest move saw Return on Capital Employed skyrocketed 394bps in 2022, then tumbled -443bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.06% in 2021, then plummeted by -1684bps to 0.94% in 2022, then surged by 36bps to 0.6% in 2023, then increased by 4bps to 0.58% in 2024, then skyrocketed by 54bps to 0.26% in 2025.
  • Business Quant data shows Return on Capital Employed for ZVRA at 0.26% in Q4 2025, 0.37% in Q3 2025, and 0.64% in Q2 2025.